Editas Medicine, Inc. (EDIT)
NASDAQ$1.46
Market Cap
$121.15M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
221 of 924
Rank in Industry
129 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
EDIT Insider Trading Activity
EDIT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $253,868 | 1 | 8 |
Sells | $346,047 | 12 | 92 |
Related Transactions
| Hopfield Jessica | director | 1 | $253,868 | 0 | $0 | $253,868 |
| Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 0 | $0 | 4 | $40,162 | $-40,162 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 0 | $0 | 2 | $69,315 | $-69,315 |
| O'Neill Gilmore Neil | CEO | 0 | $0 | 4 | $104,136 | $-104,136 |
| Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | 0 | $0 | 2 | $132,434 | $-132,434 |
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis …
Insider Activity of Editas Medicine, Inc.
Over the last 12 months, insiders at Editas Medicine, Inc. have bought $253,868 and sold $346,047 worth of Editas Medicine, Inc. stock.
On average, over the past 5 years, insiders at Editas Medicine, Inc. have bought $837,319 and sold $1.24M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hopfield Jessica (director) — $253,868.
The last purchase of 45,000 shares for transaction amount of $253,868 was made by Hopfield Jessica (director) on 2024‑05‑13.
List of Insider Buy and Sell Transactions, Editas Medicine, Inc.
| 2025-03-04 | Sale | O'Neill Gilmore Neil | CEO | 16,632 0.0193% | $1.71 | $28,452 | -12.78% | |
| 2025-03-04 | Sale | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | 4,109 0.0048% | $1.71 | $7,030 | -12.78% | |
| 2025-03-04 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 2,891 0.0034% | $1.71 | $4,946 | -12.78% | |
| 2024-12-03 | Sale | O'Neill Gilmore Neil | CEO | 1,618 0.0021% | $2.08 | $3,361 | -30.30% | |
| 2024-12-03 | Sale | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 541 0.0007% | $2.08 | $1,124 | -30.30% | |
| 2024-09-04 | Sale | O'Neill Gilmore Neil | CEO | 1,555 0.0018% | $3.42 | $5,325 | -40.00% | |
| 2024-09-04 | Sale | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 518 0.0006% | $3.42 | $1,774 | -40.00% | |
| 2024-07-25 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 11,886 0.0141% | $5.42 | $64,370 | -52.24% | |
| 2024-07-19 | Sale | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 6,619 0.0084% | $5.21 | $34,456 | -42.40% | |
| 2024-06-04 | Sale | O'Neill Gilmore Neil | CEO | 12,191 0.0142% | $5.50 | $66,997 | -44.43% | |
| 2024-06-04 | Sale | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 511 0.0006% | $5.50 | $2,808 | -44.43% | |
| 2024-05-20 | Sale | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | 22,337 0.0276% | $5.61 | $125,404 | -41.12% | |
| 2024-05-13 | Hopfield Jessica | director | 45,000 0.0541% | $5.64 | $253,868 | -42.56% | ||
| 2024-03-05 | Sale | O'Neill Gilmore Neil | CEO | 77,824 0.0981% | $9.42 | $732,884 | -58.59% | |
| 2024-03-04 | Sale | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | 20,327 0.0237% | $9.42 | $191,425 | -61.64% | |
| 2023-12-05 | Sale | Eaton Bruce | EVP, CBO AND CTO | 103 0.0001% | $10.90 | $1,122 | -50.68% | |
| 2023-11-14 | Sale | Eaton Bruce | EVP, CBO AND CTO | 695 0.0008% | $8.21 | $5,706 | -34.45% | |
| 2023-11-07 | Sale | Eaton Bruce | EVP, CBO AND CTO | 139 0.0002% | $8.40 | $1,168 | -37.33% | |
| 2023-09-06 | Sale | Eaton Bruce | EVP, CBO AND CTO | 103 0.0001% | $8.82 | $908 | -22.92% | |
| 2023-08-11 | Sale | Eaton Bruce | EVP, CBO AND CTO | 702 0.0009% | $8.59 | $6,033 | -16.65% |
Total: 172
*Gray background shows transactions not older than one year
Insider Historical Profitability
12.72%
| Hopfield Jessica | director | 67700 0.0816% | $98,842.00 | 4 | 0 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 2729808 3.2899% | $3.99M | 1 | 0 | ||
| VIKING GLOBAL PERFORMANCE LLC | 2729808 3.2899% | $3.99M | 1 | 0 | ||
| Flynn James E | 10 percent owner | 954700 1.1506% | $1.39M | 1 | 0 | +20.25% |
| MULLEN JAMES C | CEO | 75898 0.0915% | $110,811.08 | 2 | 2 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$12,784,645 | 193 | 20.49% | $111.89M | |
$30,470,407 | 140 | 20.39% | $134.78M | |
$860,541,348 | 82 | -5.10% | $132.49M | |
$54,751,750 | 62 | -1.03% | $118.75M | |
$16,245,616 | 40 | 123.58% | $122.63M |
EDIT Institutional Investors: Active Positions
| Increased Positions | 101 | +35.82% | 11M | +20.1% |
| Decreased Positions | 117 | -41.49% | 15M | -26.21% |
| New Positions | 38 | New | 4M | New |
| Sold Out Positions | 59 | Sold Out | 10M | Sold Out |
| Total Postitions | 266 | -5.67% | 53M | -6.11% |
EDIT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $14,032.00 | 8.81% | 7.31M | -716,636 | -8.93% | 2024-12-31 |
| Vanguard Group Inc | $13,100.00 | 8.22% | 6.82M | +143,392 | +2.15% | 2024-12-31 |
| Millennium Management Llc | $5,274.00 | 3.31% | 2.75M | -603,774 | -18.02% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $4,146.00 | 2.6% | 2.16M | -107,598 | -4.75% | 2024-12-31 |
| State Street Corp | $3,594.00 | 2.26% | 1.87M | -589,943 | -23.96% | 2024-12-31 |
| Geode Capital Management, Llc | $3,472.00 | 2.18% | 1.81M | -79,133 | -4.19% | 2024-12-31 |
| Goldman Sachs Group Inc | $3,430.00 | 2.15% | 1.79M | +619,011 | +53.03% | 2024-12-31 |
| Two Sigma Advisers, Lp | $3,181.00 | 2% | 1.66M | +528,000 | +46.77% | 2024-12-31 |
| Two Sigma Investments, Lp | $3,166.00 | 1.99% | 1.65M | +290,483 | +21.38% | 2024-12-31 |
| Morgan Stanley | $2,958.00 | 1.86% | 1.54M | +233,428 | +17.86% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.